New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 159-162

  Galmiche, Antoine ^a,b   Chauffert, Bruno ^a,b   Barbare, Jean Claude ^a,b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Cell death; Hepatocellular carcinoma; Resistance; Sorafenib; Treatment personalization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER RESISTANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; FERROPTOSIS; HUMAN; LIVER CELL CARCINOMA; MOLECULAR GENETICS; NONHUMAN; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY; SOMATIC MUTATION; TUMOR REGRESSION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896134891     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.12.028     Document Type: Review

References (33)

1. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. SHARP investigators study group, sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
2. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34.
3. Forner A., Llovet J.M., Bruix J. Hepatocellular Carcinoma. Lancet 2012, 379:1245-1255.
4. Thabut D., Routray C., Lomberk G., Shergill U., Glaser K., Huebert R., Patel L., Masyuk T., Blechacz B., Vercnocke A., Ritman E., Ehman R., Urrutia R., Shah V. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 2011, 54:573-585.
5. Abou-Alfa G.K., Venook A.P. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?. Lancet Oncol. 2013, 14:e283-288.
6. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L., Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
7. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., Factor V.M., Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
8. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., Calderaro J., Bioulac-Sage P., Letexier M., Degos F., Clément B., Balabaud C., Chevet E., Laurent A., Couchy G., Letouzé E., Calvo F., Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44:694-698.
9. Castillo J., Erroba E., Perugorría M.J., Santamaría M., Lee D.C., Prieto J., Avila M.A., Berasain C. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006, 66:6129-6138.
10. Ezzoukhry Z., Louandre C., Trécherel E., Godin C., Chauffert B., Dupont S., Diouf M., Barbare J.C., Mazière J.C., Galmiche A. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int. J. Cancer 2012, 131:2961-2969.
11. Huynh H., Ngo V.C., Koong H.N., Poon D., Choo S.P., Toh H.C., Thng C.H., Chow P., Ong H.S., Chung A., Goh B.C., Smith P.D., Soo K.C. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J. Hepatol. 2010, 52:79-87.
12. Newell P., Toffanin S., Villanueva A., Chiang D.Y., Minguez B., Cabellos L., Savic R., Hoshida Y., Lim K.H., Melgar-Lesmes P., Yea S., Peix J., Deniz K., Fiel M.I., Thung S., Alsinet C., Tovar V., Mazzaferro V., Bruix J., Roayaie S., Schwartz M., Friedman S.L., Llovet J.M. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 2009, 51:725-733.
13. Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 2010, 116:1315-1325.
14. Wang C., Cigliano A., Delogu S., Armbruster J., Dombrowski F., Evert M., Chen X., Calvisi D.F. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in Hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle 2013, 12:1999-2010.
15. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
16. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66:11851-11858.
17. Galmiche A., Ezzoukhry Z., François C., Louandre C., Sabbagh C., Nguyen-Khac E., Descamps V., Trouillet N., Godin C., Regimbeau J.M., Joly J.P., Barbare J.C., Duverlie G., Mazière J.C., Chatelain D. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol. Cancer Res. 2010, 8:1116-1125.
18. Hikita H., Takehara T., Shimizu S., Kodama T., Shigekawa M., Iwase K., Hosui A., Miyagi T., Tatsumi T., Ishida H., Li W., Kanto T., Hiramatsu N., Hayashi N. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010, 52:1310-1321.
19. Louandre C., Ezzoukhry Z., Godin C., Barbare J.C., Mazière J.C., Chauffert B., Galmiche A. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer 2013, 133:1732-1742.
20. Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., Morrison B., Stockwell B. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012, 149:1060-1072.
21. Shen Y.C., Ou D.L., Hsu C., Lin K.L., Chang C.Y., Lin C.Y., Liu S.H., Cheng A.L. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br. J. Cancer 2013, 108:72-81.
22. Coriat R., Nicco C., Chéreau C., Mir O., Alexandre J., Ropert S., Weill B., Chaussade S., Goldwasser F., Batteux F. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol. Cancer Ther. 2012, 11:2284-2293.
23. Stratton M.R. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331:1553-1558.
24. Curtit E., Thiery-Vuillemin A., Nguyen T., Heyd B., Pivot X., Di Martino V., Borg C. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J. Clin. Oncol. 2011, 29:330-332.
25. Arao T., Ueshima K., Matsumoto K., Nagai T., Kimura H., Hagiwara S., Sakurai T., Haji S., Kanazawa A., Hidaka H., Iso Y., Kubota K., Shimada M., Utsunomiya T., Hirooka M., Hiasa Y., Toyoki Y., Hakamada K., Yasui K., Kumada T., Toyoda H., Sato S., Hisai H., Kuzuya T., Tsuchiya K., Izumi N., Arii S., Nishio K., Kudo M. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013, 57:1407-1415.
26. Blivet-Van Eggelpoël M.J., Chettouh H., Fartoux L., Aoudjehane L., Barbu V., Rey C., Priam S., Housset C., Rosmorduc O., Desbois-Mouthon C. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J. Hepatol. 2012, 57:108-115.
27. Godin C., Dupont S., Ezzoukhry Z., Louandre C., Chatelain D., Henaut L., Sabbagh C., Regimbeau J.M., Maziere J.C., Barbare J.C., Chauffert B., Galmiche A. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. Anticancer Res. 2013, 33:1415-1420.
28. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jané-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.R., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
29. Kwon J.H., Lee N., Park J.Y., Yu Y.S., Kim J.P., Shin J.H., Kim D.S., Joh J.W., Kim D.S., Choi K.Y., Kang K.J., Kim G., Moon Y.H., Wang H.J. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS One 2013, 8:e64260.
30. Bernards R. A missing link in genotype-directed cancer therapy. Cell 2012, 151:465-468.
31. Lee J.H., Park J.Y., Kim do Y., Ahn S.H., Han K.H., Seo H.J., Lee J.D., Choi H.J. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011, 31:1144-1149.
32. Vaira V., Fedele G., Pyne S., Fasoli E., Zadra G., Bailey D., Snyder E., Faversani A., Coggi G., Flavin R., Bosari S., Loda M. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA 2010, 107:8352-8356.
33. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., Reis-Filho J.S., Kong X., Koya R.C., Flaherty K.T., Chapman P.B., Kim M.J., Hayward R., Martin M., Yang H., Wang Q., Hilton H., Hang J.S., Noe J., Lambros M., Geyer F., Dhomen N., Niculescu-Duvaz I., Zambon A., Niculescu-Duvaz D., Preece N., Robert L., Otte N.J., Mok S., Kee D., Ma Y., Zhang C., Habets G., Burton E.A., Wong B., Nguyen H., Kockx M., Andries L., Lestini B., Nolop K.B., Lee R.J., Joe A.K., Troy J.L., Gonzalez R., Hutson T.E., Puzanov I., Chmielowski B., Springer C.J., McArthur G.A., Sosman J.A., Lo R.S., Ribas A., Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012, 366:207-215.